Paul B. McCray, Jr., MD
Dr. McCray is a pulmonologist in the Department of Pediatrics at the University of Iowa. He serves as the Chief Scientific Officer for the Department of Pediatrics and holds joint appointments in the Departments of Microbiology and Immunology, and Internal Medicine. His research interests include airway innate immunity, epithelial cell biology, and the applications of genetic therapies for lung diseases. His laboratory has extensively used lentiviral and AAV vectors for gene addition to restore CFTR function. In addition, his group is using gene editing and base editing approaches to correct CFTR mutations in airway progenitor cell types. Dr. McCray is an elected member of ASCI, AAP, AAAS, and the AAM. He holds the Roy J. Carver Chair in Pulmonary Research and is supported by grants from the NIH and CFF.
| NIH/P01HL152960 | Molecular Therapies for Cystic Fibrosis Lung Disease |
| 5UH3 HL147366-05 | Delivery of CRISPR ribonucleoproteins to airway epithelia using novel amphiphilic |
| 3UH3 HL147366-05S1 | SCGE Disease Models Studies Supplement: Repair of a Nonsense Mutation using Adenine Base Editing |
| CFF MCCRAY23G0 | Adenine Base Editing Repair of a CFTR Nonsense Mutation |
| Emily's Entourage/1256174 | Enhanced Airway Transduction and Therapeutic Cargo Delivery with novel AAV Capsid |
| NIH/P30ES005605 | Environmental Health Sciences Research Center |
| NIH/P01 HL152960 | Molecular Therapies for Cystic Fibrosis Lung Disease - Project 1 - Gene editing strategies to correct CFTR mutations |
| NIH/R01 HL171035 | Adenine base edited correction of cystic fibrosis airways |
| NIH P01 HL091842 | PPG: Origins of Cystic Fibrosis Airway Disease |
